SI-544 is under clinical development by SelectION and currently in Phase I for Psoriatic Arthritis. According to GlobalData, Phase I drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SI-544’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SI-544 overview
SI-544 is under development for the treatment of cutaneous T-cell lymphoma, atopic dermatitis, plaque psoriasis, psoriasis, psoriatic arthritis and rheumatoid arthritis. It acts by targeting potassium voltage-gated channel subfamily A member 3 (Kv1.3). It was also under development for the treatment of vasculitis. It is administered through subcutaneous route.
SelectION overview
selectION is a clinical-stage biopharmaceutical company that develops novel peptide therapies for autoimmune diseases and selected cancer indications by targeting autoreactive, chronically activated T cells. The company lead product, si-544, selectively blocks Kv1.3, a key ion channel expressed in disease-associated effector memory T (TEM) cells, atopic dermatitis, psoriasis, and rheumatoid arthritis. The company’s technology platform is designed to develop potent and highly selective peptide blockers for ion channels involved in various diseases. selectION collaborates with partners such as Bachem AG and FGK Clinical Research GmbH for various aspects of its operations. It operates in the US and Germany. selectION is headquartered in San Diego, California, the US.
For a complete picture of SI-544’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
